Fibrogenic and inflammatory pathways

"Fibrogenic and inflammatory pathways" refer to the *network of molecular and cellular processes that govern tissue inflammation and the subsequent development of fibrosis* (excess extracellular matrix deposition and scarring). Key players include cytokines (such as transforming growth factor-beta [TGF-β], interleukins, tumor necrosis factor-alpha), transcription factors (such as Smad proteins), growth factors (e.g., fibroblast growth factors, FGF), chemokines, integrins, and signaling molecules in pathways such as Wnt/β-catenin, JAK/STAT, and MAPK/ERK[1][2][3][4][5][6]. These processes are not limited to a single receptor or protein but rather encompass a variety of interlinked pathways: - **TGF-β signaling** is considered the canonical driver of fibrosis, inducing fibroblast activation, myofibroblast differentiation, and collagen deposition[2][5][6]. - **Wnt/β-catenin pathway** is co-activated with TGF-β in many fibrotic conditions, promoting cell proliferation and further ECM production[2][6]. - **Cytokine networks**, especially involving IL-1β, IL-6, TNF-α, and IFN-γ, orchestrate inflammatory and immune cell recruitment, fibrogenesis, and tissue remodeling[1][5][4]. - **Chemokines** (CCL2, CCL3, CCL4, CCL20) drive immune cell migration to sites of injury and promote fibrosis[5]. - **Matrix metalloproteinases (MMPs)** and their inhibitors (TIMPs) regulate ECM turnover, affecting fibrotic outcomes[1][5]. - **Growth factors** such as FGFs and their receptors (FGFRs) are emerging therapeutic targets, influencing both fibrogenesis and inflammation[3]. - **Immune cell polarization** (e.g., Th1, Th2, M1/M2 macrophages) skews the tissue environment towards fibrosis or resolution[1][4]. **Drugs and Mechanisms of Action:** While "fibrogenic and inflammatory pathways" are not direct drug targets, numerous therapeutics intervene in these pathways by: - **Inhibiting TGF-β signaling** (antibodies, small molecules) - **Modulating cytokine activity** (anti-IL-1β, anti-TNF agents) - **Blocking chemokine receptors** - **Inhibiting kinases in downstream pathways** (JAK inhibitors, MEK inhibitors) - **Targeting FGFRs** **Therapeutic challenges** include the pleiotropic roles of these pathways in tissue repair, homeostasis, and immunity, so broad inhibition can result in undesirable side effects such as impaired wound healing or increased risk of infection[1][2][5]. In summary, "fibrogenic and inflammatory pathways" is not a druggable molecular target, but a broad conceptual term referring to myriad cellular and molecular events central to fibrosis and chronic inflammation. When requesting structured data, a more specific molecule (such as "Transforming growth factor-beta receptor 1" or "Wnt1") should be provided for precise information.

Other names

Fibrotic pathwaysInflammatory pathwaysFibrosis signaling pathwaysInflammation signaling cascades